Table 1.
Generic name | Trade name | Formula | Systematic name | Structure |
---|---|---|---|---|
Erlotinib | Tarceva® | C22H23N3O4 | N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine | |
Gefitinib | Iressa® | C22H24ClFN4O3 | N-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine | |
Afatinib | Gilotrif® | C24H25ClFN5O3 | N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide | |
Dacomitinib | C24H25ClFN5O2 | (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl}-4-(1-piperidinyl)-2-butenamide | ||
Neratinib | C30H29ClN6O3 | (2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide | ||
Osimertinib | Tagrisso™ | C28H33N7O2·CH4O3S | N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2yl]amino}phenyl)prop-2-enamide mesylate salt | |
Olmutinib | C26H26N6O2S | N-[3-({2-[4-(4-methylpiperazin-1-yl)anilino]thieno[3,2-d]pyrimidin-4-yl}oxy)phenyl]prop-2-enamide | ||
Rociletinib | C27H28F3N7O3 | N-[3-[[2-[4-(4-acetylpiperazin-1-yl)-2-methoxyanilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide |
Abbreviations: EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.